Report cover image

Netherton Syndrome

Publisher Reach Market Research
Published Oct 14, 2022
Length 20 Pages
SKU # RMR19136506

Description

MarketVue®: Netherton’s Syndrome

The MarketVue®: Netherton’s Syndrome market landscape report combines primary (KOL interviews) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Netherton’s Syndrome report is supported by 8 qualitative interviews with key opinion leaders and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Quoin Pharmaceuticals
• Lifemax Laboratories
• Sixera Pharma
• Daiichi Sankyo

Key drugs mentioned:
• Triamcinolone
• Calcineurin
• Ustekinumab (Stelara)
• Secukinumab (Cosentyx)
• QRX003
• Dupilumab (Dupixent)
• LM-030
• SXR1096
• DS-2325a


Please note: the online download version of this report is for a global site license.

Table of Contents

20 Pages
1. DISEASE OVERVIEW
A rare, inherited disorder of the skin characterized by scaling skin, bamboo hair, and increased susceptibility to infection
Figure 1.1. Clinical presentation of NS and related targets
NS falls under the category of autosomal recessive congenital ichthyoses
Figure 1.2. Classification of NS
Table 1.1. Severity of NS is typically dependent on body involvement though severity assessments exist
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. G6 diagnosed prevalent cases of NS by region
Table 2.1 Diagnosed prevalent and drug-treated patients in the G6
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1. Diagnostic work-up for NS patients
Physician insights on diagnosis of NS
Treatment of NS
Treatment overview
Figure 3.2. Treatment goals for NS
Treatment flow for NS
Figure 3.3. Treatment algorithm for NS
Upsides and downsides of current NS treatment options
Physician perspectives on off-label biologics
Figure 3.4. Reservations around off-label biologic use in NS
Key treatment dynamics that shape disease management in NS
Figure 3.5 . Must-know NS treatment dynamics for now and the future
4. UNMET NEED
Overview
Figure 4.1. Physician-reported top unmet needs in NS patients
Other unmet needs for NS
5. PIPELINE ANALYSIS
Overview
Table 5.1. Emerging NS therapies, phase 1 to phase 3
The promising future of disease-modifying biologics
Figure 5.1. Advantages of a disease-modifying biologic in NS
6. VALUE & ACCESS
Overview
Figure 6.1. Reimbursement and access considerations for emerging therapies in NS
Table 6.1. Current therapy pricing, U.S. 2021-2022
Biologics face a rigorous approval process on commercial insurance plans
Dupixent for the use of atopic dermatitis and eosinophilic esophagitis as an analogue for potential NS therapies
Figure 6.2. Commercial insurance restrictions on Dupixent’s use in AD and EoE
7. METHODOLOGY
Primary market research approach
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us